U.S. Residential REITs Stock News

Ardelyx (ARDX) is back in focus after its second quarter 2026 report showed higher revenue than a year ago and a narrower net loss, along with updated full year guidance for IBSRELA and XPHOZAH. See our latest analysis for Ardelyx. Despite Ardelyx reporting higher year over year revenue and a narrower net loss, the stock has come under pressure, with the 30 day share price return down 24.24% and the year to date share price return down 34.96%. Even so, the 5 year total shareholder return of...

Iovance Biotherapeutics recently reported its second-quarter 2026 results, with revenue rising to US$99.31 million from US$59.95 million a year earlier and net loss narrowing to US$47.32 million from US$111.66 million, while also maintaining full-year 2026 revenue guidance of US$350 million to US$370 million. For the first half of 2026, the company lifted revenue to US$170.74 million and reduced net loss to US$126.36 million versus the prior year, highlighting improving operating performance...

Microvast Holdings slipped about 1.3% to US$0.86 today, yet that small move barely hints at the pressure inside the latest earnings print. Q2 revenue came in at US$87.3m with a sharp drop in adjusted earnings before interest, tax, depreciation and amortisation, and a GAAP net loss of US$12.0m. For a high capital intensity battery manufacturer, the real headline is margin compression. Gross margin narrowed to 29.5%, while operating expenses climbed, raising fresh questions about how...

Why Morgan Stanley stock is back in focus after new bond offerings Morgan Stanley (MS) has returned to investors' watchlists after a cluster of fixed income activities, including newly announced fixed coupon notes and several recently completed medium term note offerings across different maturities. See our latest analysis for Morgan Stanley. At around $215 per share, Morgan Stanley has eased in the short term, with a 30 day share price return down 3.24% and a 7 day return down 0.91%...

Kaspi.kz came into this print with the stock already on a steady upward grind, up around 8% over the past three months, and it added another 1.4% today. That is a calm reaction for a fintech and e commerce platform that just posted quarterly revenue of 1,112,152m KZT and net income of 258,889m KZT. The real headline is profit power holding up as Kaspi.kz leans into transaction growth. Basic earnings per share of 1,362.38 KZT kept the earnings story intact, even as investors focus on how that...

Exponent (EXPO) drew investor attention after raising its full year and third quarter 2026 revenue growth guidance, while also reporting higher second quarter sales, revenue and net income, and confirming both its dividend and expanded share repurchase program. See our latest analysis for Exponent. The recent guidance upgrade and confirmed capital return plans appear to have improved sentiment around Exponent, with a 30-day share price return of 10.06% and a 90-day share price return of...

In the past quarter, Grand Canyon Education, Inc. reported higher net income of US$45.85 million and diluted EPS of US$1.75 for the second quarter and raised its full‑year 2026 earnings guidance, while also confirming it has repurchased 22,616,124 shares under its long-running buyback program. An interesting angle for investors is how management’s latest guidance for full‑year diluted EPS of US$9.93–US$10.07 now frames expectations against the company’s long-term service revenue model and...

What is driving interest in AAR (AIR) right now Recent coverage highlighting AAR (AIR) as a momentum stock pick, supported by positive earnings estimate revisions and a favorable Zacks Rank, has drawn fresh attention to the company and its recent share performance. See our latest analysis for AAR. AAR's recent move to a US$145.45 share price comes after a 35.34% 3 month share price return and a 72.23% year to date share price return. The 1 year total shareholder return of 86.45% points to...

The story with Hims & Hers Health today is the gap between the selloff and the scoreboard. The stock slipped about 4% to US$30.55 after earnings, even though Q2 revenue landed at US$753m and adjusted earnings before interest, tax, depreciation and amortization reached US$60m. That tension between a red screen and a growing telehealth platform is what matters for you as an investor. Heading into the print, Hims & Hers Health had rallied sharply over the past three months, then cooled over the...

Freedom Holding stock has more than doubled over the past five years, yet the current valuation checks suggest the shares may not offer obvious value at today’s price. With the company expanding its banking and digital ecosystem in markets such as Turkiye, investors are weighing that growth story against signals that the stock leans expensive. Freedom Holding has returned about 139.1% over the past five years, which puts recent price weakness into context as a longer term gain that investors...

What Hubbell’s latest earnings and guidance tell investors Hubbell (HUBB) reported second quarter and six month 2026 results on July 28, alongside full year guidance for sales and GAAP diluted earnings per share that gives investors fresh data to assess the stock. The company reported second quarter sales of US$1,711.8 million compared with US$1,484.3 million a year earlier, while net income was US$240.4 million compared with US$244.2 million. Diluted earnings per share from continuing...

InTest stock has been grinding lower over the past three months, yet it inched up 1.1% to close at US$13.36 after the Q2 print. That small bounce hides a more complicated story. Revenue landed at US$35.3m with adjusted earnings per share of US$0.09, while management lifted full year sales guidance to a range of US$135m to US$140m. For a company that only recently shifted back into profitability, this quarter is less about a single beat or miss and more about whether investors trust that...

In the second quarter of 2026, Corcept Therapeutics reported net income of US$42.99 million, up from US$35.15 million a year earlier, with higher basic and diluted earnings per share, while six-month net income fell to US$11.23 million from US$55.70 million. Alongside completing a multi-year US$188.58 million share repurchase program, the company raised its 2026 revenue guidance to US$1.10–1.20 billions, signaling management’s confidence in the underlying business. With Corcept now...

Ferguson Enterprises stock was riding a solid 30 day gain coming into this earnings print. The shares then dropped about 4.7% today. That is a sharp reset for a distributor that many investors view as a steady compounder in plumbing, HVAC and infrastructure. The headline is simple: earnings held up better than the price reaction suggests. Revenue reached about US$8.8b in the quarter and diluted earnings per share came in around US$3.39. Trailing 12 month earnings of just over US$10 per share...

Kinder Morgan recently joined Phillips 66 and HF Sinclair in announcing a joint venture to develop the Western Gateway Pipeline system, expanding its role in transporting energy products across key North American corridors. This collaboration highlights how Kinder Morgan can use its extensive infrastructure and strong free cash flow to pursue capital projects alongside industry peers. We’ll now examine how Kinder Morgan’s Western Gateway Pipeline joint venture could influence its investment...

UnitedHealth Group just delivered a punchy earnings headline while the stock quietly slipped. Shares closed at US$402.20, down about 1.6% on the day and modestly weaker over the past month, even as quarterly adjusted earnings per share landed at US$6.38 and operating earnings rose sharply compared with a year ago. The market looks more cautious than the numbers alone might suggest. Investors seem to be discounting the earnings strength and raised full year guidance, and instead leaning into...

FTAI Infrastructure entered this earnings season with a troubled reputation and low expectations, yet the stock nudged 1.6% higher to about US$4.37 by the close. The market is trying to price in a potential turnaround story while the income statement still shows heavy red ink. Q2 revenue came in at about US$186.8 million, but the company reported a net loss of roughly US$166.5 million and basic earnings per share of a loss of US$1.41. The real headline is not the modest price increase...

Green Dot stock barely flinched after earnings, ticking up about 1% to US$13.41, yet the numbers point to a far more dramatic story than the share price suggests. A consumer finance company that has been wrestling with rising losses just put up one of its cleanest quarterly profit lines in recent memory, with Q1 2026 basic earnings per share at US$0.96 on revenue of US$654.7m. For a business that has reported trailing twelve month net income losses, this kind of earnings power instantly...

Caledonia Mining stock closed up 1.1% at US$22.97, a calm move for what is a punchy set of numbers. The market treated today as a small win. The income statement looks more like a statement of intent. The headline is earnings power. Second quarter basic earnings per share landed at US$1.36 on revenue of about US$72.0m, with net income of US$23.8m. That keeps the trailing twelve month profit picture firm and leaves Caledonia Mining trading on a single digit P/E multiple. Short term traders saw...

The market barely flinched on C&F Financial’s earnings, with the stock edging up about 0.3%. The mood looks calm, while the fundamentals point to something more interesting. The headline is earnings power and credit quality moving in the same supportive direction. Quarterly basic earnings per share came in at about US$2.63, with net income just over US$8.5m. Net interest margin held above 4% and non performing loans stayed low in absolute terms. For a regional bank, that mix of profitability...

Tower Semiconductor Ltd. has reported its second-quarter 2026 results, with sales rising to US$460.08 million and net income reaching US$90.77 million, alongside upgraded guidance that includes a record third-quarter 2026 revenue forecast of about US$520 million and a higher 2028 target business model of US$3.60 billion in revenue and US$1.20 billion in net profit. By tying its raised 2028 revenue and profit targets to customer commitments, the company is signaling that its expanded capacity...

Fiserv stock has fallen sharply over the past year, and current valuation checks suggest the shares now lean cheap rather than expensive. With outside investors pushing for portfolio changes and management resetting expectations, the market is weighing how much of the bad news is already in the price. Fiserv has declined 60.2% over the past year, which puts the recent share price weakness at the center of any valuation discussion. On the upside, pressure from JANA Partners for portfolio...

Visa stock has delivered a 60.7% return over the past five years, yet its valuation signals are split. The Excess Returns intrinsic value estimate points to some upside, while traditional market multiples lean the other way and the broader checks do not flag Visa as a clear bargain. Over five years Visa has returned 60.7%. This puts the focus on whether the current share price already reflects much of that progress. Recent moves into stablecoin payment rails and AI driven fraud prevention...

Alpha Tau Medical earnings put recent clinical progress in context Alpha Tau Medical (NasdaqCM:DRTS) has paired a series of high profile clinical and partnership milestones with fresh half year results that show a wider net loss and higher loss per share. The company reported a net loss of US$68.75 million for the half year to June 30, 2026, compared with a loss of US$18.81 million a year earlier. Basic and diluted loss per share from continuing operations were both US$0.76, compared with...